Vesugen is the vascular member of the Khavinson bioregulator family: the tripeptide Lys-Glu-Asp (KED), sold as Cytogen capsules, a sublingual liquid and injectable vials. Its appeal is broad. Vascular aging underlies heart attacks, strokes and much of cognitive decline, so a peptide that “keeps vessels young” is an easy sell.
My verdict: Vesugen has one of the better pre-clinical files among the bioregulators, and it appears in one small human study. That still adds up to very little: no blood pressure, arterial stiffness, plaque or event data in people.
The class is covered in the peptide bioregulators overview.
At a Glance
| Property | Detail |
|---|---|
| Sequence | Lys-Glu-Asp (KED), synthetic tripeptide |
| Origin | Khavinson group, St. Petersburg; Cytogen product line |
| Proposed mechanism | Endothelial proliferation (Ki-67), normalised endothelin-1 and connexin signalling in diseased endothelium; neuroprotection in Alzheimer models (cell and mouse data) |
| Marketed for | Vascular aging, atherosclerosis, circulation, cognitive aging |
| Route | Oral capsules (Cytogen), sublingual liquid, SC injection (research vials) |
| Typical dose range | 1–2 capsules twice daily for 30 days (label); 0.5–1 mg SC daily for about 20 days (practice) |
| Evidence level | Limited: cell and mouse studies plus one small uncontrolled human study |
| Regulatory status | Capsules sold as food supplements; not an approved medicine (FDA, EMA); not named by WADA, falls under S0 |
How it works
In vascular endothelial cell cultures from young and old animals, Vesugen raised the proliferation marker Ki-67, which falls with age, and docking placed it on the promoter of the gene that codes Ki-67 [1]. In endothelium modelling atherosclerosis and restenosis, KED normalised the vasoconstrictor endothelin-1 and restored connexin-based cell contacts [2]. In aging human fibroblasts it raised differentiation markers [3], and in neuro-immune-endocrine tissue cultures it increased proliferation and reduced apoptosis, more in old than young tissue [4].
There is also a neuro thread. In 5xFAD Alzheimer mice, daily KED at 400 µg/kg tended to improve neuroplasticity and prevented dendritic spine loss [5]; in brain-cortex cultures it raised serotonin expression [6].
What the evidence shows
Human studies
| Study | Design | n | Finding | Certainty |
|---|---|---|---|---|
| Meshchaninov et al. 2015 [7] | Adults aged 41–83 with polymorbidity and organic brain syndrome; Vesugen or Pinealon | 32 | ”Anabolic” effects and slower biological-age indicators; Vesugen did better than Pinealon; a pro-oxidant signal and lower CD34+ cells were also seen | Very low: control group and randomisation not described in the abstract |
A Khavinson-group review states that oral KED improved memory and attention in older people with functional CNS disorders [8], but I found no indexed trial behind that sentence. Another paper refers to a vasoprotective effect “revealed previously in elder people” [1], again without a traceable trial.
Animal and cell studies
| Study | Model | Finding |
|---|---|---|
| Khavinson et al. 2014 [1] | Endothelial cell cultures, young and old | Ki-67 up; promoter binding modelled |
| Kozlov et al. 2016 [2] | Atherosclerotic and restenotic endothelium in vitro | Endothelin-1 normalised; connexin signalling restored |
| Khavinson et al. 2021 [5] | 5xFAD Alzheimer mice | Dendritic spine loss prevented |
Dosing
For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.
| Goal | Dose | Route | Frequency / timing | Cycle length | Basis |
|---|---|---|---|---|---|
| Vascular prevention course | 1 capsule | Oral, with meals | Twice daily | 30 days, once or twice a year | Label (supplement directions, ipept.eu) |
| “Corrective” course | 2 capsules | Oral, with meals | Two to three times daily | 30 days, repeat after 3–6 months | Label (ipept.eu; NPCRIZ Europe Cytogen directions) |
| Injectable course | 1 mg | SC injection | Once daily (some split into 500 µg twice daily) | 20 days | Practice protocol (vendor-founder protocol cited on PeptideCritic; class 1–2 mg on r/peptidebioregulators) |
| Lower injectable dose | 500 µg | SC injection | Once daily | 10–20 days or longer | Practice protocol (PeptideCritic, where users attribute this dose to Khavinson; I could not confirm that attribution) |
| Blood-pressure protocol (forum claim) | Up to 4.5 mg a day, split into doses of no more than 1 mg | SC injection | Several times daily | Not stated | Anecdotal (PeptideCritic) |
| Brain-vascular stack | Vesugen 1 mg + Pinealon 2 mg | SC injection | Once daily | Course length not stated | Anecdotal (same thread) |
| Cytogen-then-Cytomax sequence | Vesugen 1 month, then the vascular extract Ventfort | Oral | As labelled | 1 + 2–3 months | Practice protocol (vendor advice, ipept.eu) |
Custom synthesis of Vesugen is difficult because the tripeptide holds water, so vial content can be off (Longecity). Injection technique: peptide injection guide.
What people report: what works and what doesn’t
Reported to work
- Some users combining Vesugen with Livagen describe “cleaner” bloodwork after several cycles, without giving values (Steroidsgrabber forum).
- Vesugen is one of the most frequently chosen bioregulators in forum stacks and is often called the “most prominent” of them, but specific reported effects are rare (PeptideCritic).
Mixed or unclear
- Users ten days into 500 µg a day often report nothing yet and plan to raise the dose (PeptideCritic). Whether oral capsules are absorbed is debated (r/NooTopics).
Reported not to work / disappointing
- In the same general threads, others feel nothing from vascular or organ courses and question the cost.
A credible trial would randomise people at high cardiovascular risk to Vesugen or placebo and measure blood pressure, pulse wave velocity and flow-mediated dilation over at least three months.
Safety and side effects
- No adequate human safety data. The one human study noted a pro-oxidant signal and lower CD34+ cells [7].
- Do not replace proven vascular care. Blood pressure, lipid and glucose control, stopping smoking and exercise prevent heart attacks and strokes; Vesugen has no outcome data.
- Split multi-dose injections increase infection and contamination risk with unregulated vials.
- Pregnancy, active cancer: no data; avoid.
Legal and regulatory status
- US: not FDA-approved; imported capsules and “research use only” vials are not approved for human use.
- EU / Germany: not authorised as a medicine by the EMA or BfArM.
- Sport: not named on the WADA 2026 list; falls under S0.
How it fits
Cardiogen is the heart counterpart and Pinealon shares Vesugen’s only human study. For vascular aging, sauna use and the fundamentals have outcome data that no bioregulator has.
Related Articles
- Peptide Bioregulators: The Khavinson Protocol and What the Evidence Shows
- Inflammaging Guide
- The Hallmarks of Aging
- How to Inject Peptides: A Step-by-Step Guide
- Peptide Safety: What You Need to Know
Frequently asked questions
What is Vesugen?
Vesugen is the synthetic tripeptide Lys-Glu-Asp (KED) from the Khavinson bioregulator line, sold as Cytogen capsules, a sublingual liquid and injectable vials for the blood vessels.
Does Vesugen lower blood pressure or reverse atherosclerosis?
There is no trial showing either. Cell studies show effects on endothelial proliferation and endothelin-1, but no human study has measured blood pressure, arterial stiffness or plaque.
How do you take Vesugen?
The capsule directions are 1–2 capsules twice daily with meals for 30 days, repeated after 3–6 months. Injectable users commonly report 500 µg to 1 mg SC once daily for about 20 days.
Is Vesugen the same as Ventfort?
No. Ventfort is a natural vascular peptide extract in capsules (Cytomax). Vesugen is one synthetic tripeptide (Cytogen).
Can Vesugen help memory?
A Khavinson-group review states that oral KED improved memory and attention in older people with functional brain disorders, and it protected synapses in Alzheimer mice. The human data have not been published as a controlled trial.
References
- Khavinson VKh, Tarnovskaia SI, Lin’kova NS, et al. Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging (in Russian). Adv Gerontol. 2014. https://pubmed.ncbi.nlm.nih.gov/25051766/
- Kozlov KL, Bolotov II, Linkova NS, et al. Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis (in Russian). Adv Gerontol. 2016. https://pubmed.ncbi.nlm.nih.gov/28539025/
- Khavinson VKh, Linkova NS, Polyakova VO, et al. Peptides tissue-specifically stimulate cell differentiation during their aging. Bull Exp Biol Med. 2012. https://pubmed.ncbi.nlm.nih.gov/22808515/
- Chalisova NI, Lopatina NG, Kamishev NG, et al. Effect of tripeptide Lys-Glu-Asp on physiological activity of neuroimmunoendocrine system cells. Bull Exp Biol Med. 2012. https://pubmed.ncbi.nlm.nih.gov/22977872/
- Khavinson V, Ilina A, Kraskovskaya N, et al. Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer’s Disease. Pharmaceuticals (Basel). 2021. https://pubmed.ncbi.nlm.nih.gov/34071923/
- Khavinson VKh, Lin’kova NS, Tarnovskaya SI, et al. Short peptides stimulate serotonin expression in cells of brain cortex. Bull Exp Biol Med. 2014. https://pubmed.ncbi.nlm.nih.gov/24909721/
- Meshchaninov VN, Tkachenko EL, Zharkov SV, et al. Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission (in Russian). Adv Gerontol. 2015. https://pubmed.ncbi.nlm.nih.gov/26390612/
- Khavinson VK, Lin’kova NS, Umnov RS. Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer’s Disease. Bull Exp Biol Med. 2021. https://pubmed.ncbi.nlm.nih.gov/34173097/
Disclaimer: This article is for informational and educational purposes only and is not a prescription or individual medical advice. Vesugen is not approved by the FDA or the EMA.
